Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLIDE: Anti-MiHA T-cells for Relapsed Hematologic Malignancies
NCT03091933Phase 2Unknown
- Start
- Feb 2017
- Primary completion
- Mar 2018
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of GLIDE 201/44 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), mixed phenotype acute leukemia (MPAL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma (HL). Status: unknown.
02
Drugs
GLIDE 201/44
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)chronic lymphocytic leukemia (CLL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT03091933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03091933.